Status and phase
Conditions
Treatments
About
This research is studying Definity ultrasound contrast agent, which is already approved by the Food and Drug Administration (FDA) for the ultrasound evaluation of the liver and heart. This research will investigate the ability to use ultrasound imaging with ultrasound contrast agents to evaluate kidney obstruction.
Eligible participants that are enrolled will have two visits (one before and one after the planned surgery to relieve the kidney obstruction).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
10 participants in 1 patient group
Loading...
Central trial contact
Sapan N Ambani, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal